{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:26:43Z","timestamp":1791491203275,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05163-8","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T10:06:55Z","timestamp":1656324415000},"page":"1775-1783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5810","authenticated-orcid":false,"given":"Vladimira","family":"Boyadzhieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-7556","authenticated-orcid":false,"given":"Konstantin","family":"Tachkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7183-086X","authenticated-orcid":false,"given":"Nikolay","family":"Stoilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9483-9162","authenticated-orcid":false,"given":"Konstantin","family":"Mitov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-9650","authenticated-orcid":false,"given":"Rumen","family":"Stoilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8116-5138","authenticated-orcid":false,"given":"Guenka","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"5163_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G et al (2011) American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413. https:\/\/doi.org\/10.1136\/ard.2011.149765","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5163_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"issue":"8","key":"5163_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.clinthera.2017.06.013","volume":"39","author":"AF Wells","year":"2017","unstructured":"Wells AF, Curtis JR, Betts KA, Douglas K, Du Xiaoyan E, Ganguli A (2017) Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis. Clin Ther 39(8):1680-1694.e2. https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.013","journal-title":"Clin Ther"},{"key":"5163_CR4","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3389\/fphar.2018.01303","volume":"9","author":"V Boyadzhieva","year":"2018","unstructured":"Boyadzhieva V, Stoilov N, Ivanova M, Petrova G, Stoilov R (2018) Real world experience of disease activity in patients with rheumatoid arthritis and response to treatment with varios biologic DMARDs. Front Pharmacol 9:1303. https:\/\/doi.org\/10.3389\/fphar.2018.01303","journal-title":"Front Pharmacol"},{"key":"5163_CR5","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fphar.2018.00794.eCollection2018","volume":"9","author":"VV Boyadzieva","year":"2018","unstructured":"Boyadzieva VV, Stoilov N, Stoilov RM, Tachkov K, Kamusheva M, Mitov K, Petrova GI (2018) Quality of life and cost study of rheumatoid arthritis therapy with biological medicines. Front Pharmacol 9:794. https:\/\/doi.org\/10.3389\/fphar.2018.00794.eCollection2018","journal-title":"Front Pharmacol"},{"key":"5163_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2021.1847268","volume":"15","author":"C Romano","year":"2020","unstructured":"Romano C, Esposito S, Ferrara R, Cuomo G (2020) Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther 15:1\u201314. https:\/\/doi.org\/10.1080\/14712598.2021.1847268","journal-title":"Expert Opin Biol Ther"},{"key":"5163_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"J Smolen","year":"2020","unstructured":"Smolen J, Landew\u00e9 R, Bijlsma J et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"5163_CR8","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"5163_CR9","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2009) Rheumatoid arthritis: the management of rheumatoid arthritis in adults. Royal College of Physicians; National Collaborating Centre for Chronic Conditions, London"},{"key":"5163_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/TCRM.S138677","volume":"14","author":"P Kawalec","year":"2017","unstructured":"Kawalec P, Sladowska K, Malinowska-Lipien I, Brzostek T, Kozka M (2017) European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 14:15\u201329. https:\/\/doi.org\/10.2147\/TCRM.S138677","journal-title":"Ther Clin Risk Manag"},{"key":"5163_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2010.25.1.1","volume":"25","author":"SS Storage","year":"2010","unstructured":"Storage SS, Agrawal H, Furst DE (2010) Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med 25:1. https:\/\/doi.org\/10.3904\/kjim.2010.25.1.1","journal-title":"Korean J Intern Med"},{"issue":"6","key":"5163_CR12","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"key":"5163_CR13","unstructured":"FDA. Developing a framework for regulatory use of real-world evidence; Public Workshop. https:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2017-07-31\/pdf\/2017-16021.pdf. Accessed 08 Sep 2017"},{"key":"5163_CR14","unstructured":"EMA. Update on real world evidence data collection. 10 March 2016. https:\/\/ec.europa.eu\/health\/\/sites\/health\/files\/files\/committee\/stamp\/2016-03_stamp4\/4_real_world_evidence_ema_presentation.pdf. Accessed 08 Sep 2017"},{"key":"5163_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, Van\u2019t Hop MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38:44\u201348. https:\/\/doi.org\/10.1002\/art.1780380107","journal-title":"Arthritis Rheum."},{"key":"5163_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A et al (2012) American College of Rheumatology recommendations for the use of disease-modifying anti- rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625\u2013639. https:\/\/doi.org\/10.1002\/acr.21641","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5163_CR17","unstructured":"The DAS28 score (2021) https:\/\/nras.org.uk\/resource\/the-das28-score\/. Accessed 15 Jan 2021"},{"issue":"1","key":"5163_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.35465\/27.1.2019","volume":"27","author":"V Boyadzhieva","year":"2019","unstructured":"Boyadzhieva V, Stoilov N, Ivanova M, Stoilov R (2019) Treatment of rheumatoid arthritis: csDMARDS versus bDMARDS. Prospective study to evaluate disease activity. Revmatologiia 27(1):3\u201315. https:\/\/doi.org\/10.35465\/27.1.2019","journal-title":"Revmatologiia"},{"key":"5163_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","volume":"32","author":"D Aletaha","year":"2006","unstructured":"Aletaha D, Smolen J (2006) The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 32:9\u201344. https:\/\/doi.org\/10.1016\/j.rdc.2005.09.005","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"5163_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3899\/jrheum.110072","volume":"39","author":"E Ton","year":"2012","unstructured":"Ton E, Bakker M, Verstappen M et al (2012) Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol 39(1):22\u201327. https:\/\/doi.org\/10.3899\/jrheum.110072","journal-title":"J Rheumatol"},{"key":"5163_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","volume":"22","author":"DP Lubeck","year":"2004","unstructured":"Lubeck DP (2004) Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 22:27\u201338. https:\/\/doi.org\/10.2165\/00019053-200422001-00004","journal-title":"Pharmacoeconomics"},{"key":"5163_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00296-009-1176-0ff","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF (2005) The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 23:14\u20138. https:\/\/doi.org\/10.1007\/s00296-009-1176-0ff","journal-title":"Clin Exp Rheumatol"},{"key":"5163_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 1:20. https:\/\/doi.org\/10.1186\/1477-7525-1-20","journal-title":"Health Qual Life Outcomes."},{"issue":"2","key":"5163_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, Scott DL, Steer S (2014) The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 44(2):123\u2013130. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.001","journal-title":"Semin Arthritis Rheum"},{"key":"5163_CR25","first-page":"1241","volume":"34","author":"T Uhlig","year":"2007","unstructured":"Uhlig T, Loge JH, Kristiansen IS, KvienT K (2007) Quantification of reduced health-related quality-of-life in patients with rheumatoid arthritis compares to the general population. J Rheumatol 34:1241\u20131247","journal-title":"J Rheumatol"},{"key":"5163_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD (1992) The MOS 36-itemShort-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u201383","journal-title":"Med Care"},{"issue":"12","key":"5163_CR27","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.clinthera.2016.11.004","volume":"38","author":"M-C Vieira","year":"2016","unstructured":"Vieira M-C, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV (2016) Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis. Clin Ther 38(12):2628-2641.e5. https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.004","journal-title":"Clin Ther"},{"key":"5163_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8417249","author":"E Bergrath","year":"2017","unstructured":"Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G (2017) Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis. Int J Rheumatol. https:\/\/doi.org\/10.1155\/2017\/8417249","journal-title":"Int J Rheumatol"},{"issue":"4","key":"5163_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/sym13040538","volume":"13","author":"K Tachkov","year":"2021","unstructured":"Tachkov K, Boyadzhieva V, Stoilov N, Mitov K, Petrova G (2021) Is there a symmetry in disease control and quality of life of patients with rheumatoid arthritis treated with biological therapy? Symmetry 13(4):538. https:\/\/doi.org\/10.3390\/sym13040538","journal-title":"Symmetry"},{"key":"5163_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00296-012-2421-5","volume":"33","author":"K Kanecki","year":"2013","unstructured":"Kanecki K, Tyszko P, Wis\u0142owska M et al (2013) Preliminary report on a study of health-related quality of life in patients with rheumatoid arthritis. Rheumatol Int 33:429\u2013434. https:\/\/doi.org\/10.1007\/s00296-012-2421-5","journal-title":"Rheumatol Int"},{"issue":"Suppl 5","key":"5163_CR31","doi-asserted-by":"publisher","first-page":"v51","DOI":"10.1093\/rheumatology\/kez389)","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH (2019) Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford) 58(Suppl 5):v51\u2013v55. https:\/\/doi.org\/10.1093\/rheumatology\/kez389)","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5163_CR32","doi-asserted-by":"publisher","first-page":"001040","DOI":"10.1136\/rmdopen-2019-001040","volume":"5","author":"V Strand","year":"2019","unstructured":"Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R (2019) Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial. RMD Open 5(2):001040. https:\/\/doi.org\/10.1136\/rmdopen-2019-001040","journal-title":"RMD Open"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05163-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05163-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:05:10Z","timestamp":1662098710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05163-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["5163"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05163-8","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"14 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"No part of the manuscript including the table and figure were published elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards:"}}]}}